Dynavax Technologies Co. (NASDAQ:DVAX) Stock Position Reduced by Voya Investment Management LLC

Voya Investment Management LLC decreased its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 7.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 39,637 shares of the biopharmaceutical company’s stock after selling 3,379 shares during the quarter. Voya Investment Management LLC’s holdings in Dynavax Technologies were worth $506,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in Dynavax Technologies by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company’s stock valued at $51,948,000 after purchasing an additional 171,933 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Dynavax Technologies by 1.8% in the 4th quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company’s stock valued at $30,077,000 after buying an additional 41,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Dynavax Technologies by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company’s stock worth $14,750,000 after buying an additional 32,347 shares during the last quarter. Bank of Montreal Can raised its position in Dynavax Technologies by 0.5% during the fourth quarter. Bank of Montreal Can now owns 1,082,180 shares of the biopharmaceutical company’s stock valued at $13,819,000 after acquiring an additional 5,099 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Dynavax Technologies by 4.4% in the fourth quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company’s stock valued at $11,893,000 after acquiring an additional 39,513 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DVAX. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. JMP Securities dropped their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Finally, The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $24.00.

Dynavax Technologies Trading Down 2.9 %

Shares of Dynavax Technologies stock opened at $9.41 on Friday. Dynavax Technologies Co. has a 1 year low of $9.28 and a 1 year high of $14.63. The company’s fifty day simple moving average is $12.24 and its 200-day simple moving average is $12.55. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 52.28 and a beta of 1.26. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. As a group, sell-side analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.